Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.

Bulzacka E, Boyer L, Schürhoff F, Godin O, Berna F, Brunel L, Andrianarisoa M, Aouizerate B, Capdevielle D, Chéreau-Boudet I, Chesnoy-Servanin G, Danion JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Le Gloahec T, Llorca PM, Mallet J, Misdrahi D, Rey R, Richieri R, Passerieux C, Roux P, Yazbek H, Leboyer M, Fond G; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group.

Schizophr Bull. 2016 May 3. pii: sbw029. [Epub ahead of print]

PMID:
27143795
2.

Functional brain substrate of quality of life in patients with schizophrenia: A brain SPECT multidimensional analysis.

Faget-Agius C, Boyer L, Richieri R, Auquier P, Lançon C, Guedj E.

Psychiatry Res. 2016 Mar 30;249:67-75. doi: 10.1016/j.pscychresns.2016.02.005. Epub 2016 Feb 12.

PMID:
27000309
3.

[Switching and combining strategies of antidepressant medications].

Charpeaud T, Moliere F, Bubrovszky M, Haesebaert F, Allaïli N, Bation R, Nieto I, Richieri R, Saba G, Bellivier F, Bennabi D, Holtzmann J, Camus V, Courtet P, Courvoisier P, d'Amato T, Doumy O, Garnier M, Bougerol T, Lançon C, Haffen E, Leboyer M, Llorca PM, Vaiva G, El-Hage W, Aouizerate B.

Presse Med. 2016 Mar;45(3):345-53. doi: 10.1016/j.lpm.2016.02.003. Epub 2016 Mar 16. French.

PMID:
26995511
4.

[Other therapeutic strategies].

Saba G, Nieto I, Bation R, Allaïli N, Bennabi D, Moliere F, Richieri R, Holtzmann J, Bubrovszky M, Camus V, Charpeaud T, Courtet P, Courvoisier P, Haesebaert F, Doumy O, El-Hage W, Garnier M, d'Amato T, Bougerol T, Lançon C, Haffen E, Llorca PM, Vaiva G, Bellivier F, Leboyer M, Aouizerate B.

Presse Med. 2016 Mar;45(3):323-32. doi: 10.1016/j.lpm.2016.02.005. Epub 2016 Mar 16. French.

PMID:
26995510
5.

[How to define treatment-resistant depression?].

Holtzmann J, Richieri R, Saba G, Allaïli N, Bation R, Moliere F, Nieto I, Bellivier F, Bennabi D, Bubrovszky M, Camus V, Charpeaud T, Courvoisier P, Haesebaert F, Doumy O, Courtet P, El-Hage W, Garnier M, d'Amato T, Lançon C, Leboyer M, Llorca PM, Vaiva G, Bougerol T, Aouizerate B, Haffen E.

Presse Med. 2016 Mar;45(3):354-9. doi: 10.1016/j.lpm.2016.02.002. Epub 2016 Mar 9. French.

PMID:
26970938
6.

[Potentiation strategies].

Doumy O, Bennabi D, El-Hage W, Allaïli N, Bation R, Bellivier F, Holtzmann J, Bubrovszky M, Camus V, Charpeaud T, Courvoisier P, d'Amato T, Garnier M, Haesebaert F, Bougerol T, Lançon C, Moliere F, Nieto I, Richieri R, Saba G, Courtet P, Vaiva G, Leboyer M, Llorca PM, Aouizerate B, Haffen E.

Presse Med. 2016 Mar;45(3):333-44. doi: 10.1016/j.lpm.2016.02.004. Epub 2016 Mar 10. French.

PMID:
26970936
7.

Sensory Gating Capacity and Attentional Function in Adults With ADHD: A Preliminary Neurophysiological and Neuropsychological Study.

Micoulaud-Franchi JA, Lopez R, Cermolacce M, Vaillant F, Péri P, Boyer L, Richieri R, Bioulac S, Sagaspe P, Philip P, Vion-Dury J, Lancon C.

J Atten Disord. 2016 Feb 19. pii: 1087054716629716. [Epub ahead of print]

PMID:
26896149
8.

Corrigendum: Neural substrate of quality of life in patients with schizophrenia: a magnetisation transfer imaging study.

Faget-Agius C, Boyer L, Wirsich J, Ranjeva JP, Richieri R, Soulier E, Confort-Gouny S, Auquier P, Guye M, Lançon C.

Sci Rep. 2016 Feb 15;6:21055. doi: 10.1038/srep21055. No abstract available.

9.

A structural equation modelling approach to explore the determinants of quality of life in schizophrenia.

Alessandrini M, Lançon C, Fond G, Faget-Agius C, Richieri R, Faugere M, Metairie E, Boucekine M, Llorca PM, Auquier P, Boyer L.

Schizophr Res. 2016 Mar;171(1-3):27-34. doi: 10.1016/j.schres.2016.01.012. Epub 2016 Jan 15.

PMID:
26781001
10.

Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set.

Fond G, Godin O, Brunel L, Aouizerate B, Berna F, Bulzacka E, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Le Strat Y, Micoulaud-Franchi JA, Misdrahi D, Rey R, Richieri R, Passerieux C, Schandrin A, Schürhoff F, Tronche AM, Urbach M, Vidalhet P, Llorca PM, Leboyer M; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group.

J Affect Disord. 2016 Feb;191:209-15. doi: 10.1016/j.jad.2015.11.017. Epub 2015 Nov 26.

PMID:
26674214
11.

Does sensory gating have a protective effect against hallucinatory behavior in schizophrenia?

Faugère M, Micoulaud-Franchi JA, Boyer L, Cermolacce M, Richieri R, Faget C, Vion-Dury J, Lançon C.

Clin Neurophysiol. 2016 Feb;127(2):1746-8. doi: 10.1016/j.clinph.2015.10.031. Epub 2015 Oct 19. No abstract available.

PMID:
26529999
12.

Perceptual abnormalities related to sensory gating deficit are core symptoms in adults with ADHD.

Micoulaud-Franchi JA, Lopez R, Vaillant F, Richieri R, El-Kaim A, Bioulac S, Philip P, Boyer L, Lancon C.

Psychiatry Res. 2015 Dec 15;230(2):357-63. doi: 10.1016/j.psychres.2015.09.016. Epub 2015 Sep 13.

PMID:
26416589
13.

Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort.

Godin O, Leboyer M, Gaman A, Aouizerate B, Berna F, Brunel L, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Le Strat Y, Llorca PM, Misdrahi D, Rey R, Richieri R, Passerieux C, Schandrin A, Schürhoff F, Urbach M, Vidalhet P, Girerd N, Fond G; FACE-SZ group.

Schizophr Res. 2015 Oct;168(1-2):388-94. doi: 10.1016/j.schres.2015.07.047.

PMID:
26255568
14.

Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review.

Fond G, Micoulaud-Franchi JA, Brunel L, Macgregor A, Miot S, Lopez R, Richieri R, Abbar M, Lancon C, Repantis D.

Psychiatry Res. 2015 Sep 30;229(1-2):12-20. doi: 10.1016/j.psychres.2015.07.006. Epub 2015 Jul 8. Review.

PMID:
26187342
15.

Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study.

Faugere M, Micoulaud-Franchi JA, Alessandrini M, Richieri R, Faget-Agius C, Auquier P, Lançon C, Boyer L.

Sci Rep. 2015 Jun 4;5:10793. doi: 10.1038/srep10793.

16.

Association of metabolic syndrome with sensory gating deficits in patients with chronic schizophrenia.

Micoulaud-Franchi JA, Faugere M, Boyer L, Cermolacce M, Richieri R, Faget C, Philip P, Vion-Dury J, Lancon C.

Psychoneuroendocrinology. 2015 Jul;57:125-33. doi: 10.1016/j.psyneuen.2015.04.005. Epub 2015 Apr 15.

PMID:
25917886
17.

Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia.

Micoulaud-Franchi JA, Faugere M, Boyer L, Fond G, Richieri R, Faget C, Cermolacce M, Philip P, Vion-Dury J, Lancon C.

Schizophr Res. 2015 Jun;165(1):94-6. doi: 10.1016/j.schres.2015.03.018. Epub 2015 Apr 10.

PMID:
25864954
18.

Sensory gating in adult with attention-deficit/hyperactivity disorder: Event-evoked potential and perceptual experience reports comparisons with schizophrenia.

Micoulaud-Franchi JA, Vaillant F, Lopez R, Peri P, Baillif A, Brandejsky L, Steffen ML, Boyer L, Richieri R, Cermolacce M, Bioulac S, Aramaki M, Philip P, Lancon C, Vion-Dury J.

Biol Psychol. 2015 Apr;107:16-23. doi: 10.1016/j.biopsycho.2015.03.002. Epub 2015 Mar 9.

PMID:
25766264
19.

Effects of clozapine on perceptual abnormalities and sensory gating: a preliminary cross-sectional study in schizophrenia.

Micoulaud-Franchi JA, Aramaki M, Geoffroy PA, Richieri R, Cermolacce M, Faget C, Ystad S, Kronland-Martinet R, Lancon C, Vion-Dury J.

J Clin Psychopharmacol. 2015 Apr;35(2):184-7. doi: 10.1097/JCP.0000000000000270.

PMID:
25587694
20.

Determinants of brain SPECT perfusion and connectivity in treatment-resistant depression.

Richieri R, Boyer L, Faget-Agius C, Farisse J, Mundler O, Lançon C, Guedj E.

Psychiatry Res. 2015 Feb 28;231(2):134-40. doi: 10.1016/j.pscychresns.2014.11.013. Epub 2014 Dec 3.

PMID:
25561373
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk